allergic asthma atopic asthma
Conditions
Interventions
Study duration: 1-2 weeks. 2 visits of approximately 1 hour.
Blood Collection (venapunction): 2x, about 11 ml each time.
Finger prick: 2x
Sponsors
Novartis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients: 1. Male or female subjects who are aged *18 years. 2. Subjects who are diagnosed with atopic asthma or other atopic condition for a minimum of 6 months prior to study entry. There should be documented evidence of sensitization to one or more specific allergens.;Inclusion criteria for healthy volunteers: N/A for the Netherlands. Besides, adults only (minimum age of 18) will be included in the Netherlands.
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients: 1. Subjects who have received treatment with omalizumab or other anti-IgE antibody treatment in the past 6 months. 2. Subjects who have elevated serum IgE levels for reasons other than allergic conditions (e.g., parasite infections, hyperimmunoglobulin E syndrome, Wiskott-Aldrich syndrome, or bronchopulmonary aspergillosis).;Exclusion criteria for healthy volunteers: N/A for the Netherlands.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoints: * Total IgE concentration in capillary blood measured with the POCT device. * Total IgE concentration in venous blood measured with the reference method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints: * Device usability questionnaire. | — |
Countries
Netherlands
Outcome results
None listed